EI
VRTX icon

Ethic Inc’s Vertex Pharmaceuticals VRTX Stock Holding History

Ethic Inc’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4M Buy
20,947
+3,051
+17% +$1.35M 0.13% 145
2026
Q1 		$7.99M Buy
17,896
+1,913
+12% +$892K 0.13% 172
2025
Q4 		$7.25M Buy
15,983
+2,012
+14% +$867K 0.11% 184
2025
Q3 		$5.47M Buy
13,971
+2,476
+22% +$1.03M 0.09% 221
2025
Q2 		$5.07M Buy
11,495
+58
+0.5% +$26.7K 0.09% 233
2025
Q1 		$5.54M Sell
11,437
-11,553
-50% -$5.38M 0.11% 201
2024
Q4 		$9.26M Buy
22,990
+3,197
+16% +$1.48M 0.19% 107
2024
Q3 		$8.27M Sell
19,793
-1,369
-6% -$658K 0.21% 99
2024
Q2 		$9.92M Buy
21,162
+1,369
+7% +$594K 0.23% 82
2024
Q1 		$8.27M Buy
19,793
+2,157
+12% +$912K 0.21% 99
2023
Q4 		$7.18M Buy
17,636
+1,131
+7% +$418K 0.21% 99
2023
Q3 		$5.74M Buy
16,505
+1,769
+12% +$619K 0.2% 108
2023
Q2 		$5.19M Buy
14,736
+1,422
+11% +$479K 0.19% 123
2023
Q1 		$4.19M Buy
13,314
+4,611
+53% +$1.38M 0.17% 152
2022
Q4 		$2.51M Buy
8,703
+1,372
+19% +$418K 0.14% 196
2022
Q3 		$2.12M Buy
7,331
+1,326
+22% +$382K 0.14% 175
2022
Q2 		$1.69M Buy
6,005
+3,656
+156% +$979K 0.12% 226
2022
Q1 		$613K Buy
2,349
+157
+7% +$37.3K 0.04% 410
2021
Q4 		$481K Sell
2,192
-1,894
-46% -$368K 0.04% 420
2021
Q3 		$741K Sell
4,086
-124
-3% -$24.2K 0.08% 278
2021
Q2 		$849K Buy
4,210
+749
+22% +$157K 0.1% 240
2021
Q1 		$744K Buy
3,461
+966
+39% +$212K 0.13% 196
2020
Q4 		$590K Sell
2,495
-104
-4% -$23.9K 0.16% 169
2020
Q3 		$707K Buy
2,599
+231
+10% +$63.7K 0.27% 97
2020
Q2 		$687K Buy
2,368
+1,420
+150% +$385K 0.39% 60
2020
Q1 		$226K Buy
+948
New +$217K 0.19% 166

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Ethic Inc's VRTX Position: Q2 2026 in Review

Ethic Inc increased its Vertex Pharmaceuticals (VRTX) stake by 17% in Q2 2026, buying an estimated $1.35M and bringing the position to 20,947 shares worth $10.4M. The position accounts for 0.13% of the portfolio, ranked #145.

Ethic Inc first reported a position in VRTX in Q1 2020 and has held it in 26 quarters since. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Ethic Inc held 20,947 shares of Vertex Pharmaceuticals worth $10.4M as of Q2 2026.
  • Ethic Inc bought 3,051 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.35M.
  • Vertex Pharmaceuticals made up 0.13% of Ethic Inc's portfolio in Q2 2026, its #145 holding.
  • Ethic Inc first reported a position in Vertex Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Ethic Inc's 13F filing for Q2 2026, filed 29 Jul 2026.